Over the past decade, immunotherapy has fundamentally reshaped the oncology landscape, establishing immune checkpoint inhibitors—particularly those targeting the PD-1/PD-L1 pathway—as standard treatments across multiple malignancies. While early advances were primarily observed in metastatic settings, recent years have marked a clear transition toward earlier disease stages, including neoadjuvant, adjuvant, and perioperative strategies.
By 2025–2026, the field has entered a new phase characterized by incremental but clinically meaningful progress. Rather than introducing entirely new classes of checkpoint inhibitors, current innovation is driven by optimized combinations, novel drug formulations, and integration with other therapeutic platforms, such as antibody–drug conjugates and cellular therapies. At the same time, treatment selection is increasingly guided by biomarker-defined populations, reflecting a shift toward precision immuno-oncology.
These developments are now being rapidly incorporated into clinical practice, with multiple recent FDA approvals and updates in National Comprehensive Cancer Network guidelines (2025–2026) redefining standards of care across several tumor types.
Pembrolizumab (anti–PD-1)
Pembrolizumab remains the most extensively integrated immunotherapy across National Comprehensive Cancer Networkguidelines, supported by a wide body of randomized Phase III trials spanning multiple tumor types and disease stages. Its clinical evolution reflects the broader trajectory of immuno-oncology—from metastatic disease into curative-intent settings, including neoadjuvant and perioperative strategies.
In early-stage triple-negative breast cancer, the KEYNOTE-522 trial established pembrolizumab in combination with neoadjuvant chemotherapy followed by adjuvant monotherapy as a new standard of care. The trial demonstrated a clear improvement in event-free survival, which translated into a statistically significant overall survival benefit with longer follow-up.
Key results (KEYNOTE-522):
- 36-month EFS: 84.5% vs 76.8%
- 5-year OS: 86.6% vs 81.7%
These findings led to full regulatory approval and NCCN Category 1 recommendation, firmly positioning pembrolizumab in early-stage TNBC management.
In resectable non-small cell lung cancer, the KEYNOTE-671 trial further extended the role of pembrolizumab into the perioperative setting. When combined with platinum-based chemotherapy, pembrolizumab significantly improved both event-free survival and overall survival compared with chemotherapy alone. This trial marked a critical shift toward integrating immunotherapy into potentially curative treatment paradigms and is now reflected in NCCN 2025–2026 guidelines.
In urothelial carcinoma, the combination of pembrolizumab with enfortumab vedotin was evaluated in the EV-302 trial / KEYNOTE-A39 trial study. This combination demonstrated one of the most substantial survival improvements observed in advanced bladder cancer, redefining first-line treatment.
Key results (EV-302 / KEYNOTE-A39):
- Median OS: 31.5 months vs 16.1 months
This magnitude of benefit has led to rapid incorporation into NCCN guidelines as a preferred regimen in metastatic urothelial carcinoma.
More recently, in muscle-invasive bladder cancer, the KEYNOTE-B15 trial (EV-304) trial evaluated perioperative pembrolizumab in combination with enfortumab vedotin. The study demonstrated statistically significant improvements in both event-free survival and overall survival compared with standard neoadjuvant cisplatin-based chemotherapy. These findings support ongoing regulatory review and are expected to further expand NCCN recommendations into earlier-stage bladder cancer.
Key results (KEYNOTE-B15 / EV-304):
- Significant improvement in event-free survival
- Significant improvement in overall survival
Collectively, these trials illustrate how pembrolizumab continues to evolve beyond a checkpoint inhibitor into a central component of multi-modality cancer treatment, driving improvements not only in advanced disease but increasingly in curative-intent settings.
Nivolumab (anti–PD-1)
Nivolumab remains a foundational immunotherapeutic agent, with deep integration into National Comprehensive Cancer Network guidelines, particularly in melanoma and gastrointestinal malignancies. Its clinical development has been defined by pivotal Phase III trials demonstrating not only survival benefit, but also unprecedented durability of response across tumor types.
In advanced melanoma, the CheckMate 067 trial established dual immune checkpoint blockade with nivolumab and ipilimumab as a transformative strategy. This randomized Phase III study demonstrated a significant overall survival advantage compared with monotherapy, with long-term follow-up confirming one of the most durable outcomes observed in solid tumors.
Key results (CheckMate 067):
- Median OS: 71.9 months (combination arm)
- 10-year OS rate: >50%
These findings have redefined expectations in metastatic melanoma and continue to support NCCN Category 1 recommendations for combination immunotherapy.
In the adjuvant setting for esophageal and gastroesophageal junction cancers, the CheckMate 577 trial evaluated nivolumab following chemoradiotherapy and surgical resection. The trial demonstrated a significant improvement in disease-free survival, effectively doubling DFS compared with placebo, and established nivolumab as a standard of care in this high-risk population.
Key results (CheckMate 577):
- Median DFS: 22.4 months vs 11.0 months
This study led to regulatory approval and incorporation into NCCN guidelines for adjuvant therapy.
In advanced gastric and gastroesophageal cancers, the CheckMate 649 trial further expanded the role of nivolumab into first-line treatment. When combined with chemotherapy, nivolumab significantly improved overall survival compared with chemotherapy alone, with sustained benefit observed on long-term follow-up.
Key results (CheckMate 649):
- Median OS: 14.4 months vs 11.1 months
These results supported the adoption of nivolumab-based chemo-immunotherapy as a first-line standard in NCCN treatment algorithms.
Taken together, these trials highlight nivolumab’s role as a cornerstone immunotherapy agent, with consistent evidence supporting its use across metastatic, adjuvant, and first-line settings, and with long-term survival outcomes that continue to redefine benchmarks in oncology.
Durvalumab (anti–PD-L1)
Durvalumab has progressively expanded from a consolidation strategy into earlier-stage and perioperative treatment paradigms, with strong integration into National Comprehensive Cancer Network guidelines.
In unresectable stage III non-small cell lung cancer, the PACIFIC trial established durvalumab as consolidation therapy after chemoradiotherapy, demonstrating durable survival benefit with long-term follow-up.
Key results (PACIFIC):
- Median PFS: 16.8 vs 5.6 months
- Median OS: 47.5 vs 29.1 months
- 5-year OS rate: 42.9% vs 33.4%
More recently, the NIAGARA trial evaluated perioperative durvalumab in muscle-invasive bladder cancer, confirming its role in earlier-stage disease.
Key results (NIAGARA):
- Event-free survival significantly improved (HR ~0.68)
- Pathologic complete response rate: ~37% vs ~27%
- Overall survival: early positive trend (immature data)
These results supported FDA approval (2025) and NCCN 2026 integration, reinforcing durvalumab as a key agent in both locally advanced and perioperative settings.
Atezolizumab (anti–PD-L1)
Atezolizumab continues to hold a central role across multiple tumor types, supported by pivotal Phase III trials that have shaped its integration into National Comprehensive Cancer Network guidelines. Its clinical impact is particularly well established in hepatocellular carcinoma and non-small cell lung cancer, where it has redefined first-line treatment strategies through combination and biomarker-driven approaches.
In hepatocellular carcinoma, the IMbrave150 trial demonstrated that the combination of atezolizumab with bevacizumab significantly improved survival outcomes compared with sorafenib, establishing a new global standard of care.
Key results (IMbrave150):
- Median OS: 19.2 vs 13.4 months
- Median PFS: 6.8 vs 4.3 months
- Objective response rate (ORR): ~30% vs ~11%
- Significant reduction in risk of death
These results led to rapid adoption as a Category 1 NCCN-recommended regimen in first-line advanced hepatocellular carcinoma.
In non-small cell lung cancer, the IMpower110 trial evaluated atezolizumab monotherapy in patients with PD-L1–selected tumors. The study confirmed a survival advantage over chemotherapy in patients with high PD-L1 expression, reinforcing a biomarker-driven treatment approach.
Key results (IMpower110):
- Median OS (high PD-L1 population): 20.2 vs 13.1 months
- Durable responses with longer duration of response compared with chemotherapy
- Favorable safety profile consistent with PD-L1 inhibition
Together, these data support the continued role of atezolizumab as a key immunotherapy agent, particularly in combination strategies and biomarker-selected populations, maintaining its strong presence in NCCN treatment algorithms across multiple malignancies.
Dostarlimab (anti–PD-1)
Dostarlimab represents one of the most striking examples of biomarker-driven immunotherapy, particularly in mismatch repair–deficient (dMMR) tumors, where immune checkpoint blockade can lead to profound and durable responses.
In locally advanced rectal cancer, a landmark Phase II study evaluated dostarlimab in patients with dMMR tumors, a population known to be highly sensitive to immunotherapy. Rather than combining with chemotherapy or radiation, dostarlimab was administered as a single agent with the goal of achieving organ preservation.
Key results (Phase II dMMR rectal cancer study):
- Clinical complete response (cCR): 100% (initial cohort)
- No patients required chemoradiotherapy or surgery
- Responses were durable, with no progression or recurrence observed during follow-up
- Favorable safety profile with no unexpected immune-related toxicities
These unprecedented results have led to rapid incorporation into National Comprehensive Cancer Network guidelines as a non-operative management strategy in carefully selected patients with dMMR rectal cancer.
More broadly, this study represents a paradigm shift—from cytotoxic and surgical approaches toward immune-based, organ-preserving strategies, highlighting the power of precise biomarker selection in modern oncology.
Relatlimab + Nivolumab (LAG-3 + PD-1 inhibition)
The combination of Relatlimab and Nivolumab represents a next-generation checkpoint blockade strategy, expanding beyond PD-1 inhibition alone by targeting the LAG-3 immune checkpoint pathway. This dual inhibition approach is designed to overcome adaptive immune resistance mechanisms within the tumor microenvironment.
The Phase III RELATIVITY-047 trial evaluated this combination in patients with previously untreated advanced melanoma, comparing it directly with nivolumab monotherapy.
Key results (RELATIVITY-047):
- Median PFS: 10.2 vs 4.6 months
- Risk reduction for disease progression or death: ~25%
- Improved progression-free survival across key subgroups
- Manageable safety profile, with lower toxicity compared to CTLA-4–based combinations
These findings established nivolumab plus relatlimab as a new standard first-line option in advanced melanoma, now incorporated into National Comprehensive Cancer Network guidelines.
Importantly, this trial marks a shift toward dual immune checkpoint inhibition beyond CTLA-4, opening the door to more refined, mechanism-based combination strategies in immuno-oncology.
Enfortumab Vedotin + Pembrolizumab (ADC + Immunotherapy)
The combination of Enfortumab vedotin and Pembrolizumab represents a major advance in immuno-oncology, integrating targeted cytotoxic delivery with immune checkpoint blockade. By coupling an antibody–drug conjugate directed against nectin-4 with PD-1 inhibition, this strategy simultaneously enhances tumor cell killing and promotes anti-tumor immune activation.
This paradigm was established in the Phase III EV-302 trial / KEYNOTE-A39 trial study, which evaluated the combination as first-line therapy in patients with locally advanced or metastatic urothelial carcinoma, compared with standard platinum-based chemotherapy.
Key results (EV-302 / KEYNOTE-A39):
- Median OS: 31.5 vs 16.1 months
- Median PFS: significantly improved vs chemotherapy
- Objective response rate (ORR): substantially higher than chemotherapy
- Risk of death: reduced by approximately 50%
- Durable responses observed across subgroups
These results established this combination as a new first-line standard of care, now incorporated into National Comprehensive Cancer Network guidelines.
Importantly, this trial highlights a broader shift in oncology toward rational combination strategies, where antibody–drug conjugates and immunotherapy are integrated to overcome resistance and deliver deeper, more durable responses.
KEYNOTE-B15: Perioperative Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer
Tarlatamab (DLL3-targeted bispecific T-cell engager)
Tarlatamab represents a new generation of immunotherapy designed to redirect T cells directly toward tumor cells by targeting DLL3, a protein highly expressed in small cell lung cancer (SCLC). Unlike checkpoint inhibitors, this approach does not rely on pre-existing anti-tumor immunity but actively brings T cells into proximity with cancer cells, enabling direct cytotoxic activity.
Clinical development in heavily pretreated SCLC populations has demonstrated clinically meaningful activity, particularly in a disease historically characterized by limited treatment options and poor outcomes after progression on standard therapies.
Key results (DeLLphi clinical studies):
- Objective response rate (ORR): ~40% in relapsed/refractory SCLC
- Median duration of response: ~9–10 months
- Rapid onset of responses observed in a significant proportion of patients
- Manageable safety profile, with cytokine release syndrome as the most notable adverse event
These results supported FDA approval in 2025, marking one of the first successful implementations of bispecific T-cell engager therapy in a solid tumor. Early integration into clinical practice and treatment pathways reflects growing interest in immune-redirection strategies beyond PD-1/PD-L1 blockade.
Importantly, tarlatamab signals a broader shift in immuno-oncology toward active immune engagement, where therapies are designed not only to release immune inhibition but to direct and amplify immune effector function within the tumor microenvironment.
Lifileucel (Tumor-Infiltrating Lymphocyte Therapy)
Lifileucel represents a major advance in cellular immunotherapy, being the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. This approach involves harvesting autologous T cells from the tumor microenvironment, expanding them ex vivo, and reinfusing them following lymphodepleting chemotherapy, thereby restoring and amplifying tumor-specific immune responses.
Its clinical development has focused on patients with advanced melanoma who have progressed on prior immune checkpoint inhibitors and, in many cases, targeted therapies—an area of high unmet need.
Key results (pivotal lifileucel trials – C-144-01):
- Objective response rate (ORR): ~31% in heavily pretreated melanoma
- Complete responses (CR): ~5–8%
- Median duration of response: not reached at extended follow-up
- Durable responses observed beyond 12–24 months in a substantial subset
- Disease control rate (DCR): ~80%
These results supported FDA approval and subsequent incorporation into National Comprehensive Cancer Network-aligned treatment pathways as an option for patients with advanced melanoma after progression on standard therapies.
Importantly, lifileucel marks a shift toward personalized, cell-based immunotherapy, where treatment is tailored using a patient’s own tumor-reactive lymphocytes. This strategy highlights the evolving role of cellular therapies in solid tumors, complementing checkpoint inhibitors and expanding the immunotherapy landscape beyond antibody-based approaches.